 The U.S Army Medical Research and Development Command has awarded CytoSorbents Corporation NASDAQ: CTSO, a Defense Health Agency DHA Sequential Phase II Small Business Innovation Research SBIR contract of 1.5 million over 28 months. The funding will be used to advance the development of the Kontrol platform to treat severe hyperkalemia induced by traumatic injury and acute kidney injury in austere medicine. 